Phase I Study to Evaluate the Safety and Efficacy of NK Cell Therapy in Acute Myeloid Leukemia (AML). is a PHASE1 clinical asset sponsored by Institute of Hematology & Blood Diseases Hospital, China in AML, Adult, Minimal Residual Disease. SEO and diligence focus: CD33/CLL1 dual CAR-NK cell, Cyclophosphamid, Fludarabine, Cytarabine, CD33 CAR-NK cell, super NK cell, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.